Prescrire International

Prescrire International is no longer posting on X. Follow us on our other social media accounts and our website

[Prescrire International @PrescrireInt]

Revision of European pharmaceutical legislation: an opportunity to transform the system of R&D incentives ➡ https://t.co/y6VlwH1Nf5

[Prescrire International @PrescrireInt]

Enjoy these features, and more, in our upcoming issues ➡ https://t.co/eQHGHDgE2Q

[Prescrire International @PrescrireInt]

About 60 out of 100 000 articles are retracted after publication. Unfortunately, those who read or cite them are not always aware of their retracted status ➡ https://t.co/hE3d4tK62o

[Prescrire International @PrescrireInt]

Dupilumab in severe asthma in children: helpful and without risk of infections or cancer ? ➡ https://t.co/sjyR0I7Ljq

[Prescrire International @PrescrireInt]

The WHO urges governments to stand up to health-harming corporations ➡ https://t.co/DIVrABOp3u

[Prescrire International @PrescrireInt]

Valoctocogene roxaparvovec (Roctavian°) in haemophilia A? ➡ https://t.co/qcgxFM6z4s

[Prescrire International @PrescrireInt]

In 2024, a study using a British general practice database, linked to hospitalisation and mortality data, investigated several known adverse effects of neuroleptics in patients with dementia who were aged 50 years or older ➡ https://t.co/DUTgzeUEjM

[Prescrire International @PrescrireInt]

RSVPreF3/AS01E vaccine (Arexvy°) in the prevention of RSV infections from 60 years of age ➡️ https://t.co/9oTQZgnXGQ

[Prescrire International @PrescrireInt]

Discover Prescrire International's Free Special Edition
Specially selected texts to introduce you to our wholly independent journal on drugs and health policy in Europe ➡ https://t.co/PKxqbZa4nR

[Prescrire International @PrescrireInt]

📷 In the January issue of Prescrire International:
- RSV vaccines from 60 years of age
- Dupilumab better avoided in children with asthma
- An opportunity to transform the system of R&D incentives
This month's contents 📷 https://t.co/WmdXykNeXo

[Prescrire International @PrescrireInt]

Enjoy these features, and more, in our upcoming issues ➡ https://t.co/MjXYCiF95s

[Prescrire International @PrescrireInt]

Receive the free, monthly Newsletter from the editors of Prescrire International, a critical eye on new drugs authorised in Europe. Sign up here ➡ https://t.co/9NCDoiApS5

[Prescrire International @PrescrireInt]

Solifenacin + tamsulosin (Vecalmys°/Vesomni°) in benign prostatic hyperplasia: not acceptable ➡https://t.co/QHM3VU8KpE

[Prescrire International @PrescrireInt]

Environmental impact of drugs: taking drug utilisation data into account ➡ https://t.co/r3v0W3cg8H

[Prescrire International @PrescrireInt]

Short-term interruption of treatment with a xaban or dabigatran: sometimes fatal thrombosis ➡ https://t.co/kJ5myXq8GI

[Prescrire International @PrescrireInt]

The American Psychiatric Association (APA) has been producing successive versions of the Diagnostic and Statistical Manual of Mental Disorders (DSM) since 1952. The aim of the DSM is to propose a definition for every psychiatric disorder ➡ https://t.co/mT8mSBNpMz

[Prescrire International @PrescrireInt]

Finerenone (Kerendia°) in chronic kidney disease with albuminuria associated with type 2 diabetes ➡ https://t.co/l1CNxK3wSg

[Prescrire International @PrescrireInt]

🔎 In the october issue of Prescrire International:
- Finerenone in diabetic kidney disease?
- Carbamazephine during pregnancy: neurodevelopmental disorders
- Environmental impact of drugs
This month's contents ➡ https://t.co/f314Ps9YOT

[Prescrire International @PrescrireInt]

Enjoy these features, and more, in our upcoming issues ➡ https://t.co/ScNs6ayEro

[Prescrire International @PrescrireInt]

In the interests of patients, Prescrire's contribution emphasises two points that are fundamental to the quality and safety of health care, and that the EMA must take into account while developing its forthcoming guideline on "non-­inferiority" trials ➡ https://t.co/46DknUUly8